Material for capturing circulating blood cells, preparation process and use

The alumina ceramic material with grafted aptamers and antibodies addresses the limitations of existing CTC capture methods by enabling safe, large-volume CTC elimination, reducing metastasis risk and improving chemotherapy effectiveness.

FR3099373B1Inactive Publication Date: 2024-11-08I CERAM
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
FR2019008831
Authority / Receiving Office
FR · FR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2019-08-01
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current techniques for capturing circulating tumor cells (CTCs) are limited to small blood volumes and cannot effectively eliminate them from a patient's blood, lacking adaptability to different cancer types and stages, and are not biocompatible for large-scale blood treatment, posing risks of metastasis and chemotherapy inefficacy.

Method used

An alumina ceramic material grafted with aptamers and/or antibodies, using a trialkoxysilane binding molecule, ensures non-porous and biocompatible capture of CTCs, allowing treatment of the entire blood volume without inducing hemolysis or coagulation, and can be customized for specific cancer markers.

Benefits of technology

The material effectively captures and eliminates CTCs from large blood volumes, reducing metastasis risk and enhancing chemotherapy efficacy by minimizing CTCs, while maintaining biocompatibility and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000029_0000
    Figure 00000029_0000
  • Figure 00000029_0001
    Figure 00000029_0001
  • Figure 00000030_0000
    Figure 00000030_0000
Patent Text Reader

Abstract

The present invention relates to a material selected from alumina ceramic grafted with at least one aptamer, at least one antibody or their combination for the capture of circulating foreign cells, preferably circulating tumor cells, the method of preparing such a material, its use and device comprising it.
Need to check novelty before this filing date? Find Prior Art

Description

Title of the invention: Material for capturing circulating cells in blood, preparation method and use FIELD OF THE INVENTION

[0001] The field of the invention is that of materials allowing the capture of foreign cellular elements circulating in the blood, preferably circulating tumor cells. More precisely, the present invention relates to an alumina ceramic material onto which is grafted at least one aptamer and / or at least one antibody allowing the capture of foreign cellular elements circulating in the blood, preferably circulating tumor cells. The present invention also relates to a method for preparing such a material, a device comprising such a material as well as the use of the material according to the invention for the capture of foreign cellular elements circulating in the blood, preferably circulating tumor cells. TECHNICAL BACKGROUND

[0002] Cancer is a disease resulting from the excessive and uncontrolled proliferation of abnormal or malignant cells that can affect any part of the body. When these malignant cells multiply, they form a mass referred to as a "tumor." Sometimes cells detach from the tumor and pass into the bloodstream and / or lymphatic system, spreading throughout the body and forming secondary tumors also called metastases. These cells are referred to as circulating tumor cells (CTCs). It is estimated that 95% to 98% of solid tumors produce CTCs.

[0003] It is also estimated that worldwide, 70% of breast cancer deaths, as well as 80% of lung cancer deaths and 40% of prostate cancer deaths, are due to metastases.

[0004] Furthermore, the effectiveness of cancer treatment depends mainly on the possibility of destroying the tumor. Surgery allows the primary tumor to be removed. However, the discovery of a metastasis, even a single one, means that circulating tumor cells are circulating in the blood or lymph, and can at any time nest in another organ to form another metastasis. In this case, surgery is not enough to treat the cancer and it is necessary to move on to heavier chemotherapy treatments. The presence of circulating tumor cells in the blood and / or lymph therefore means that there is a risk for the patient to develop metastases in other organs.

[0005] Circulating tumor cells are also of interest in terms of prognosis. For example, in the case of breast cancer, a threshold of 5 CTCs in a 7.5 ml sample of peripheral blood is considered a good prognosis for the patient. Above this threshold, it is considered a poor prognosis.

[0006] To date, there are many counting technologies but few known methods for capturing and eliminating circulating tumor cells. For example, we know the technique for identifying and counting circulating tumor cells marketed under the name CELLSEARCH® System, which is currently the only technique validated by the American Food and Drug Administration (FDA). This technique uses immunomagnetic beads, i.e. magnetic nanoparticles coated with antibodies directed against the EpCam, CD45, cytokeratin 8 and / or cytokeratin 19 proteins, making it possible to accurately detect and count CTCs in a 7.5 ml blood sample. This technique is limited to the detection and counting of CTCs originating from breast, colon or prostate cancer.

[0007] Mention may also be made of the use of beads or nanoparticles on which antibodies are fixed to enable circulating tumor cells to be fixed for their study and characterization. Such beads are, for example, marketed by the company QIAGEN under the names AdnaTest® BreastCancerSelect or AdnaTest® Breast-CancerDetect or for the enrichment of breast cancer CTCs from a sample of peripheral blood from a patient. The beads have on their surface antibodies specific for the ligands GA733-2, MUC-1 and HER-2.

[0008] Other techniques implement the attachment of aptamers for the detection of circulating tumor cells, these aptamers being attached to silica oxide or graphene oxide chips, or magnetic columns comprising iron oxide particles.

[0009] Due in particular to the volume of the sample tested, which cannot exceed 10 ml, all these techniques are limited to diagnostic purposes or to monitoring the development of cancer in a patient who has undergone surgery and / or chemotherapy. However, none of these techniques can capture circulating tumor cells from a patient's blood in order to eliminate them. Indeed, these techniques cannot be used in practice to rid a patient's blood of circulating tumor cells, and indeed do not have this objective.

[0010] However, the capture and elimination of such cells from the body could prevent and / or reduce the risk of tumor development, which would greatly improve the chances of survival of a cancer patient.

[0011] Such an objective requires taking into account a certain number of factors. First, the physiological, chemical and molecular characteristics of circulating tumor cells depend on the one hand on the type of primary cancer from which they originate. detached and on the other hand the stage of progression of the disease. Indeed, cancer cells from a newly formed cancer may present different markers from cells from a less recent cancer. The system developed must therefore be adaptable. Secondly, the capture of circulating tumor cells for clinical purposes requires the development of a system allowing the treatment of the total blood volume of a patient, i.e. between 3 and 5L of blood per patient, or even the treatment of several times this volume as is the case in the context of renal dialysis. Thirdly, the capture system must be perfectly biocompatible and inert with respect to blood elements.In particular, the material allowing the capture of circulating tumor cells must not react chemically or physically with blood elements, preferably must not retain blood elements other than circulating tumor cells and must not release elements potentially dangerous for the patient into the extracorporeal blood circulation.

[0012] In addition to circulating tumor cells, blood can sometimes be contaminated by the presence of foreign, potentially pathogenic cellular elements, such as viruses, fungi, bacteria. Blood can also include potentially toxic chemical elements such as lead, arsenic, pesticides, insecticides, etc.

[0013] International application WO 2017 / 186626 relates to an extracorporeal blood filtration device for capturing circulating tumor cells present in the blood of a patient, as well as a method for capturing circulating tumor cells using such a system. According to this technique, the device comprises one or more chambers as well as a propeller in the form of an Archimedes screw, the walls of the chambers as well as the screw having on their surface a combination of six antibodies and / or aptamers for capturing circulating tumor cells present in the blood of a patient. However, this application does not disclose a concrete example of a material allowing the implementation of this technique.

[0014] There is therefore a need to create materials that can capture and retain circulating tumor cells. Summary of the invention

[0015] These objectives are achieved by the material according to the present invention, its use as well as a method of grafting said material and its use.

[0016] The present invention relates to an alumina ceramic material grafted with at least one aptamer, at least one antibody or their combinations.

[0017] Advantageously, the at least one aptamer, the at least one antibody or their com- combination is grafted to the alumina ceramic material by a linker molecule.

[0018] Advantageously, the linking molecule is a trialkoxysilane of formula N-N+ =NL-Si(ORl)(OR2)(OR3) in which L denotes a linear, branched or cyclic divalent hydrocarbon radical comprising 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, and RI, R2, R3 are identical or different and represent a linear or branched alkyl group comprising 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms.

[0019] Preferably, the linker molecule is 3-azidopropyltriethoxysilane.

[0020] Advantageously, the alumina ceramic material has at least one surface in contact with the blood of a patient, said surface not being porous.

[0021] Preferably, the surface of the material in contact with the patient's blood has zero open porosity.

[0022] Preferably, the surface of the material in contact with the patient's blood is impermeable.

[0023] Advantageously, the alumina ceramic is a dense alumina.

[0024] Advantageously, the material is grafted with at least one aptamer.

[0025] Advantageously, the at least one aptamer is single-stranded DNA.

[0026] Advantageously, the at least one antibody is formed by the whole antibody, the Fv fragment, Fab fragment or F(ab')2 fragment.

[0027] Advantageously, the at least one aptamer or at least one antibody is a substituted aptamer or an antibody substituted by at least one linear, branched or cyclic hydrocarbon group comprising a terminal alkyne function having the formula -C=CH and from 3 to 20 carbon atoms, preferably from 10 to 15 carbon atoms, said hydrocarbon group being optionally substituted by one or more heteroatoms.

[0028] Advantageously, the heteroatom(s) may be chosen from O, S, N, P or a halogen, preferably from O, N, P, preferably the heteroatom(s) are oxygen atoms.

[0029] Preferably, the at least one aptamer is substituted at its 5' end.

[0030] Advantageously, the at least one aptamer or the at least one antibody is capable of binding to at least one of the proteins chosen from mucin 1 (MUC-1), EpCam, HER-2, EGFR, vimentin, E-cadherin, N-cadherin, OB-cadherin, CD44v6, CD44v8, PSA, cytokeratin 8, cytokeratin 19, ABC-G2 and combinations thereof.

[0031] Preferably, the at least one aptamer binds at least to the mucin 1 (MUC-1) protein.

[0032] Advantageously, the at least one aptamer or at least one antibody is linked to at least one marking molecule.

[0033] Preferably, the at least one aptamer is linked to at least one labeling molecule. at its 3' end.

[0034] Advantageously, the at least one marking molecule is a fluorophore.

[0035] Advantageously, the fluorophore is chosen from phycoerythrin (PE), fluorescein isothiocyanate (FITC), the Alexa Fluor™ range, green fluorescent protein (or GFP) or combinations thereof.

[0036] Preferably, the fluorochrome is fluorescein isothiocyanate (FITC).

[0037] The present invention also relates to a process for preparing the material according to the invention comprising the grafting of the alumina ceramic with at least one aptamer, at least one antibody or their combination.

[0038] Advantageously, the at least one aptamer, at least one antibody or their combination is grafted to said alumina ceramic material by a binding molecule, said method comprising at least the following steps: - binding of the binding molecule to the alumina ceramic material by reaction of one or more alkoxy functions of the binding molecule with one or more hydroxyl groups of the alumina ceramic material; and - binding of the aptamer or antibody to the binding molecule by click chemistry reaction.

[0039] Advantageously, the at least one aptamer or the at least one antibody is a substituted aptamer or an antibody substituted by at least one linear, branched or cyclic hydrocarbon group comprising a terminal alkyne function having the formula -C=CH and from 3 to 20 carbon atoms, preferably from 10 to 15 carbon atoms, said hydrocarbon group being optionally substituted by one or more heteroatoms.

[0040] Advantageously, the aptamer or antibody is substituted and the binding of the substituted aptamer or substituted antibody to the binding molecule is carried out by reaction of the terminal alkyne function of the substituted aptamer with the terminal azide function of formula -N=N+=N of the binding molecule.

[0041] Advantageously, the step of binding the binding molecule to the alumina ceramic material is carried out in the presence of an organic solvent.

[0042] Preferably, the organic solvent is toluene.

[0043] Preferably, the step of binding the binding molecule to the alumina ceramic material is carried out under anhydrous conditions.

[0044] Advantageously, the step of binding the binding molecule to the alumina ceramic material is carried out under an inert atmosphere.

[0045] Advantageously, the method according to the invention may comprise a step before the step of binding the binding molecule to the alumina ceramic material in which the alumina material is previously heated, preferably to a temperature above 100°C.

[0046] Advantageously, the step of binding the binding molecule to the alumina ceramic material is carried out at a temperature ranging from 30 to 120°C, preferably from 50 to 100°C.

[0047] Advantageously, the step of binding the substituted aptamer or the substituted antibody to the binding molecule is carried out in the presence of one or more organic solvents, preferably acetonitrile, or an amine, preferably trimethylamine or triethylamine.

[0048] Advantageously, the step of binding the substituted aptamer or the substituted antibody to the binding molecule is carried out in the presence of a supported or unsupported catalyst.

[0049] Advantageously, the catalyst is a metal catalyst, preferably a copper catalyst.

[0050] Preferably, the copper catalyst is copper I bromotris(triphenylphosphine).

[0051] Advantageously, the step of binding the substituted aptamer or the substituted antibody to the binding molecule is carried out at a temperature ranging from 30 to 120°C, typically from 50 to 100°C.

[0052] Advantageously, the step of binding the binding molecule to the alumina ceramic material is carried out before the step of binding the substituted aptamer or the substituted antibody with the binding molecule.

[0053] The present invention also relates to a device for capturing circulating foreign cells comprising the material as described above and at least one housing.

[0054] Preferably, the capture device is a device for capturing circulating tumor cells.

[0055] Advantageously, the device is an extracorporeal capture device.

[0056] Advantageously, the housing of the device according to the invention has at least one inlet for blood to enter the housing and an outlet for blood to exit the housing.

[0057] Advantageously, the device according to the invention also has a tool for capturing circulating foreign cells.

[0058] Advantageously, the housing has a tubular shape.

[0059] Advantageously, the capture tool is in the form of a propeller or an Archimedes screw comprising an axis of rotation.

[0060] Advantageously, the rotation axis comprises a magnet at each of its ends.

[0061] Advantageously, the housing of the device comprises a magnet.

[0062] The present invention also relates to the material according to the invention for its use in the capture of circulating foreign cells, preferably cells circulating tumors.

[0063] Advantageously, the material according to the invention is used to improve the effectiveness of chemotherapy.

[0064] Advantageously, the material according to the invention is used to reduce the risk of metastasis formation.

[0065] The present invention also relates to an aptamer, an antibody or their combination grafted onto an alumina ceramic material according to the invention for the capture of circulating foreign cells, preferably circulating tumor cells.

[0066] Advantageously, the circulating tumor cells come from breast cancer, lung cancer, prostate cancer, colorectal cancer, bladder cancer, stomach cancer, or melanoma.

[0067] The present invention also relates to a method for capturing circulating foreign cells, preferably CTCs, using the material according to the invention. DETAILED DESCRIPTION OF THE INVENTION

[0068] The present invention relates to an alumina ceramic material grafted with at least one aptamer, at least one antibody or their combination. Preferably, the alumina ceramic has an alumina percentage greater than 95% by weight, more preferably greater than 99% by weight.

[0069] In the context of the invention, alumina has the formula A12O3. Alumina ceramic typically has hydroxyl groups on its surface.

[0070] The alumina ceramic material according to the invention has the advantage of being biocompatible and chemically inert with respect to bodily fluids. Thus, unlike silica, alumina ceramic does not degrade over time and will therefore not release any elements into the patient's blood. Furthermore, silica cannot be shaped in a dense manner like ceramic.

[0071] According to one embodiment, the material according to the invention can be grafted by a combination of aptamers, a combination of antibodies or a combination of aptamers and antibodies.

[0072] The material according to the invention has at least one surface in contact with the patient's blood. The at least one aptamer, the at least one antibody or their combinations are grafted onto the surface in contact with the patient's body fluids. Although the present invention finds its application for the treatment of a patient's blood, it is understood that it can also be used to treat any other body fluid of a patient. In the context of the present invention, the term "body fluid" means any fluid produced by the human body such as blood, serum, urine, lymph, chyle, etc.

[0073] In one embodiment, the material according to the invention has a surface in contact with the blood of a patient, said surface not being porous. In the context of the present invention, a surface is considered to be non-porous when the surface has pores whose size is less than 5 μm, preferably less than 2 μm, more preferably less than 1 μm. In a particularly preferred embodiment, the size of the pores of the surface of the alumina ceramic material is zero. The open porosity of the surface in contact with the blood of the patient is therefore zero. The size of the pores can be measured by microscopy with image analysis and measurements of the “diameters”. The porosity can also be measured by mercury porosimetry. The porosity is defined by the ratio between the volume occupied by the pores and the total volume of the ceramic, the total volume comprising the sum of the volume of the pores and the volume of the alumina.

[0074] The alumina ceramic material according to the invention is therefore biocompatible and hemocompatible: it does not cause any hemolysis or coagulation reaction. In the context of the present invention, a material is considered to be hemocompatible if it allows the preservation of the acid-base osmotic balances of the blood, if it does not alter or capture plasma proteins, formed elements of the blood, cells of the vascular tissue and if it does not activate the hemostasis and complement systems. In other words, the low porosity of the surface of the material in contact with the patient's blood, and preferably its absence of porosity, allows the material according to the invention to be used for the treatment of the volume of this blood in complete safety for the patient.

[0075] Indeed, according to the invention, the alumina ceramic material grafted with at least one aptamer or antibody is intended to come into contact with the patient's blood to capture circulating foreign cells, preferably CTCs. If the material according to the invention were porous, blood elements of the patient would be likely to be retained in the pores of the material. However, an objective of the present invention is to provide a material capturing only circulating foreign cells, preferably CTCs, in the patient's blood and not the patient's blood elements such as red blood cells, leukocytes, platelets, chemical elements, without inducing an undesirable reaction such as hemolysis, denaturation of plasma proteins or aggregation of platelets for example. In other words, the surface of the material according to the invention is impermeable to blood, that is to say that it does not allow blood to pass through.

[0076] An alumina ceramic particularly suitable for carrying out the invention may be a dense ceramic. In the context of the present invention, an alumina ceramic material is considered to be dense if its density is greater than 3.5 g / cm3, preferably at least 3.8 g / cm3. The density is measured by dividing the mass of the material by its volume. Preferably, the ceramic material complies with DIN VDE 0335.

[0077] The present invention therefore provides a material that is biocompatible and chemically inert with respect to the patient's bodily fluids, and in particular blood. Grafting the alumina ceramic material according to the invention with at least one aptamer or at least one antibody makes it possible to capture the undesirable elements circulating in the blood of a patient. In the context of the present invention, the term "capture" means that the foreign cell binds to the aptamer and / or the antibody in a sufficiently strong manner so that it does not detach itself to return to the patient's blood. In particular, when the at least one aptamer or antibody is specific for a CTC marker, the material according to the invention makes it possible to capture the CTCs circulating in the patient's blood and to rid the patient of them.The use of the material according to the invention can therefore be used for therapeutic purposes to eliminate CTCs, or at least reduce the number of CTCs in a patient's blood in order to reduce the risk of metastasis formation. The material according to the invention also makes it possible to improve the effectiveness of chemotherapy. Indeed, by reducing the number of CTCs in the patient's blood, the material according to the invention allows chemotherapeutic substances to be more effective without increasing their dosage.

[0078] The material according to the invention can also be grafted with several different aptamers or antibodies, or a combination of antibodies and aptamers. The aptamers or antibodies can be either: - directed against different parts of the same target molecule, - be directed against different molecules, or - a combination of these two options, i.e. the material according to the invention may comprise several aptamers or antibodies, some of which will be directed against the same target while the other aptamers or antibodies will be directed against another target.

[0079] Preferably, the aptamer or antibody is tailor-made for each patient. In other words, the aptamer or antibody can be designed to react specifically with markers expressed by cells circulating in the patient's blood.

[0080] The aptamers and / or antibodies may be distributed uniformly on the surface of the material or heterogeneously. Preferably, the aptamers or antibodies are distributed homogeneously on the surface of the ceramic so as to effectively capture and remove foreign elements from the blood. The concentration of the aptamers and / or antibodies grafted to the surface of the material may be between 0.01 nmol / cm2 and 10 nmol / cm2, preferably between 0.1 nmol / cm2 and 1 nmol / cm2, more preferably between 0.3 nmol / cm2 and 0.5 nmol / cm2.

[0081] The material according to the invention can also be grafted with at least one anti-inflammatory agent. coagulant to prevent the patient's blood from clotting during the implementation of the material for the capture and removal of CTCs. Preferably, the at least one anticoagulant agent may be selected from heparin, an anti-vitamin K agent, a direct factor Xa inhibitor, a direct thrombin inhibitor or combinations thereof.

[0082] The anti-vitamin K agent may be selected from coumarin derivatives, indanedione derivatives or combinations thereof. The coumarin derivatives may be acenocoumarol and warfarin. The indanedione derivatives may be fluindione.

[0083] Any anticoagulant agent authorized by health authorities is suitable for implementing the present invention.

[0084] Aptamer

[0085] According to a preferred embodiment of the invention, the ceramic material is grafted with one or more aptamers.

[0086] In the context of the present invention, an aptamer is a synthetic oligonucleotide for binding a specific ligand. The term "oligonucleotide" means a DNA or RNA sequence of one hundred base pairs or less. Their selectivity and binding properties are comparable to those of antibodies. The oligonucleotide may be single-stranded ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). Preferably, the aptamer is single-stranded DNA.

[0087] The aptamer is custom-made to be specific for the markers expressed by the tumor cells. Those skilled in the art are familiar with the methods for synthesizing and selecting aptamers. Among these methods, the SELEX method (for "Systematic Evolution of Ligands by EXponential enrichment") should be mentioned. Briefly, this selection method is an iterative method, based on repeating the steps until the desired aptamer is obtained. It requires a library of oligonucleotides whose 5' and 3' ends are known and whose central sequence is random. The random nature of the central sequence is obtained by reacting the four bases of the DNA or RNA during the elongation step. The four bases of DNA are adenine, cytosine, guanine and thymine and the four bases of RNA are adenine, cytosine, guanine and uracil.This allows oligonucleotides of different lengths and sequences to be obtained. The next step is to select the oligonucleotides that bind with the best possible affinity to the target molecule. Several techniques known to those skilled in the art allow the separation of oligonucleotides that have recognized the target molecule from other oligonucleotides that do not recognize the target. Examples of separation methods include native gel affinity chromatography, membrane separation, or the use of magnetic beads. The oligonucleotides are then separated from the . molecule of interest and are amplified by cloning or PCR. The oligonucleotide selection and amplification steps are repeated several times to obtain oligonucleotides with high affinity for the target molecule. The selected oligonucleotides are called aptamers. The SELEX technique provides good results and oligonucleotides with a very low dissociation constant.

[0088] The aptamer has selectivity and affinity properties comparable to those of antibodies. The specificity and affinity properties of aptamers allow their use to capture circulating foreign cells, preferably CTCs, in a patient's blood and bind them strongly enough so that a circulating cell does not detach from the aptamer to which it is bound and does not return to the patient's blood. Thus, the material according to the invention makes it possible to capture and remove circulating foreign cells, preferably CTCs, from a patient's blood.

[0089] Antibodies

[0090] According to one embodiment, the material according to the invention can be grafted with one or more antibodies. The at least one antibody is formed by a whole antibody, an Fv fragment, a Fab fragment or an F(ab')2 fragment.

[0091] The term "antibody", as used herein, refers to immunoglobulin molecules consisting of four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain is composed of a heavy chain variable (VH) region and a heavy chain constant region. The heavy chain constant region is composed of three domains, CH1, CH2, and CH3. Each light chain is composed of a light chain variable (VL) region and a light chain constant region. The light chain constant region is composed of a CL domain. The VH and VL regions can be subdivided into regions of hypervariability, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs).Each VH and VL is composed of three CDRs and four FRs, arranged amino-terminally to carboxy-terminally in the following order: FRI, CDR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0092] Antibody portions, such as Fv, Fab, and F(ab')2 fragments, may be prepared from whole antibodies using conventional techniques, such as papain or pepsin digestion of whole antibodies. In addition, Fv, Fab, and F(ab')2 antibodies or antibody portions may be obtained using conventional recombinant DNA techniques. "Fv fragment" means the smallest fragment consisting of the heavy and light chains of the variable region and retaining the binding properties of the antibody. "Fab fragment" means the monovalent antibody fragment formed by the entire light chain (variable part and constant part) and a portion of the heavy chain. "Fragment F(ab')2 » the association of two Fab fragments linked by the hinge region of the antibody.

[0093] The term "isolated antibody," as used herein, means an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to MUC-1 is substantially free of antibodies that specifically bind to antigens other than MUC-1). In addition, an isolated antibody may be substantially free of other cellular and / or chemical substances.

[0094] The antibodies suitable for implementing the invention may be polyclonal or monoclonal antibodies, produced according to any method well known to those skilled in the art. Preferably, the at least one antibody is a monoclonal antibody.

[0095] The antibody for implementing the invention is preferably humanized.

[0096] The antibody may further be directed toward a marker specific to a cell foreign to the body in order to capture foreign cells circulating in the blood and remove these circulating foreign cells.

[0097] Preferably, the antibody or antibody fragment Fv, Fab or F(ab')2 is grafted to the material according to the invention via a linker molecule.

[0098] Substitution

[0099] Preferably, the aptamer or antibody is substituted by at least one linear, branched or cyclic hydrocarbon group comprising a terminal alkyne function having the formula -C=CH and from 3 to 20 carbon atoms, preferably from 10 to 15 carbon atoms, said hydrocarbon group possibly comprising at least one heteroatom. The presence of the terminal alkyne function makes it possible to react the aptamer or antibody with the binding molecule covalently.

[0100] The heteroatom(s) may be chosen from O, P, N, S and a halogen, preferably from O, N, P, more preferably the heteroatom(s) are oxygen atoms.

[0101] For the purposes of the present invention, a “hydrocarbon group” is a group comprising carbon and hydrogen atoms, linear, branched or cyclic, substituted or unsubstituted by one or more heteroatoms. The hydrocarbon group may be saturated or unsaturated.

[0102] According to one embodiment, the aptamer or the antibody is substituted by a linear or branched hydrocarbon group comprising a terminal alkyne function and comprising from 3 to 20 carbon atoms, said hydrocarbon chain being substituted by at least one function chosen from hydroxyl and carbonyl functions. Preferably, the branch(es) of the hydrocarbon group when present on the hydrocarbon group, comprise from 1 to 5 carbon atoms, preferably from 1 to 3 carbon atoms, advantageously 1 to 2 carbon atoms.

[0103] According to one embodiment, the aptamer or the antibody is substituted by a linear or branched alkyl group comprising a terminal alkyne function and at least one carbonyl function and at least one hydroxyl function, said alkyl group comprising from 10 to 15 carbon atoms. Preferably, the branch(es) of the alkyl group when present on the alkyl group, comprise from 1 to 5 carbon atoms, preferably from 1 to 3 carbon atoms, advantageously 1 to 2 carbon atoms.

[0104] The substituted aptamer or substituted antibody may be commercially available or synthesized according to methods well known to those skilled in the art.

[0105] Thus, the grafting of the aptamer or antibody to the material is sufficiently strong to prevent detachment of the material and is found in the patient's peripheral blood.

[0106] Circulating foreign cells

[0107] The material according to the invention makes it possible to capture any element circulating in the blood. The material according to the invention makes it possible in particular to capture cellular elements foreign to the body and found in the blood.

[0108] In particular, the foreign cells may be a virus, a bacterium, a fungus, a circulating tumor cell, an animal cell foreign to the organism or their combinations.

[0109] According to a preferred embodiment, the circulating foreign cells are circulating tumor cells. Indeed, tumor cells are often distinguished from “normal” cells of the tissue concerned because they have different cell markers.

[0110] Markers

[0111] The at least one aptamer or the at least one antibody are preferably directed towards markers of circulating foreign cells.

[0112] In one embodiment, the aptamer or antibody may be directed against a capsid protein of a virus or against a protein, sugar, or glycoprotein of the capsid of a virus to trap the virus. For example, the aptamer or antibody may be directed against hemagglutinin.

[0113] In the context of the present invention, the term "sugar" refers to monosaccharides, disaccharides and polysaccharides. Sugars include, but are not limited to, sucrose, glucose, dextrose and other sugars.

[0114] In the context of the present invention, a protein designates a biological macromolecule, formed of one or more polypeptide chains. Each of these chains is made up of the chain of amino acid residues linked together by peptide bonds. In the context of the present invention, an amino acid is a carboxylic acid which also has an amine functional group. Such organic compounds therefore have both a carboxyl group -COOH and an amine group, for example a primary amine -NH2 or a secondary amine -NH-. In the context of the present invention, a glycoprotein is a protein bearing one or more oligoside groups, an oligoside being an oligomer formed from a number of monosaccharides, identical or different, by alpha or beta glycosidic bond.

[0115] The aptamer or antibody may also be directed against a molecule present on the surface of a bacterium. As an example of a bacterial marker, mention may be made of lipopolysaccharides (LPS) present in the outer membrane of Gram-negative bacteria.

[0116] Regarding circulating tumor cells (CTCs), there are different markers depending on the type of cancer the patient has. The scientific literature provides the skilled person with the specific markers that he must look for depending on a specific type of cancer. Among the markers to which aptamers can bind are EpCam (for EPithelial Cell Adhesion Molecule), HER-2 (for Human Epidermal Growth Factor Receptor 2), EGFR (for Epithelial Growth Factor Receptor), Mucin-1 (MUC-1), Vimentin, E-cadherin, N-cadherin, OB-cadherin, CD44v6, CD44v8, PSA (for Prostate Specific Antigen), Cytokeratin 8, Cytokeratin 19, FABC-G2 and combinations thereof.

[0117] The CD44v6 marker is expressed by colon cancer cells. The HER2 and CD44v8 markers are specifically expressed by breast cancer cells. The EpCam, EGFR and E-cadherin markers are specific to epithelial cells and are expressed on the surface of many cells from carcinomas, including non-small cell lung cancer, for example.

[0118] Preferably, the aptamer or antibody binds to mucin 1 protein. Mucin 1 protein is a glycoprotein encoded by the MUC1 gene in humans, expressed at the apical pole of many epithelial cells.

[0119] This protein is particularly overexpressed by circulating tumor cells from breast cancer, lung cancer, prostate cancer, colorectal cancer, bladder cancer, stomach cancer, and melanoma.

[0120] More specifically, circulating tumor cells express a version of MUC-1 with reduced and anarchic glycosylation, which makes it particularly antigenic and differentiates it well from the MUC-1 protein expressed by normal cells. The MUC-1 protein is therefore a good discriminating marker for circulating tumor cells.

[0121] Preferably, the anti-mucin aptamer 1 is a 72-base single-stranded DNA oligonucleotide having the following sequence: 5' GGGAGACAAGAAT AAACGCTCAAGC AGTTGATCCTTTGGATACCCTGG TTCGACAGGAGGCTC ACAACAGGC3'

[0122] The material according to the invention grafted by the aptamer or the antibody binding to MUC-1 therefore makes it possible to capture the CTCs expressing this marker and to eliminate a significant number of CTCs from different cancers.

[0123] In a particularly advantageous embodiment, the material according to the invention is grafted with several aptamers and / or antibodies making it possible to recognize several different markers and / or different parts of a marker.

[0124] Binding molecule

[0125] The at least one aptamer and / or the at least one antibody may be grafted to said material by a linker molecule. The linker molecule makes it possible to covalently link the aptamer and / or the antibody to the accessible hydroxyl functions present on the surface of the alumina ceramic. The linker molecule further acts as a spacer between the aptamer or the antibody and the biocompatible material. Indeed, an aptamer or an antibody is a bulky molecule. Direct binding of the aptamer or the antibody to the material would create a steric hindrance which would make the aptamer or the antibody poorly available, or even unavailable, to bind to circulating cellular elements.

[0126] According to one embodiment, the aptamer is linked to the linker molecule at its 5' end.

[0127] The linker molecule preferably comprises a reactive function capable of reacting with the substituted aptamer or the substituted antibody by a click chemistry reaction. Thus, the linker molecule preferably comprises a terminal azide function -N=N+=N capable of reacting with the terminal alkyne of the substituted aptamer or the substituted antibody to form a triazole-type ring.

[0128] Preferably, the linking molecule is a trialkoxysilane of formula N = N + = NL-Si(OR1)(OR2)(OR3) in which L denotes a linear, branched or cyclic divalent hydrocarbon group comprising 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, and RI, R2, R3 are identical or different and represent a linear or branched alkyl group comprising 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms.

[0129] In the context of the invention, an alkyl group denotes a monovalent saturated hydrocarbon chain.

[0130] In the context of the invention, an alkoxy group of formula -(OR) denotes an alkyl group linked to an oxygen atom.

[0131] According to one embodiment, L is a divalent, linear or branched group comprising from 1 to 10 carbon atoms. Preferably, L is a divalent, linear or branched alkyl group comprising from 1 to 10 carbon atoms. More preferably, L is a linear alkyl group comprising from 1 to 6 carbon atoms.

[0132] Preferably, the linker molecule is 3-azidopropyltriethoxysilane (AzPTES).

[0133] The binding molecule may be commercially available or synthesized according to methods well known to those skilled in the art.

[0134] Labeling of the aptamer or antibody

[0135] For the implementation of the present invention, the aptamer or the antibody may also be conjugated to one or more colored or fluorescent marker(s). Preferably, the aptamer is labeled at its 3' end. The labeling of the aptamer or the antibody may be carried out according to any method well known to those skilled in the art. The labeling of the aptamer may in particular be carried out by a click chemistry reaction between the marker and the aptamer.

[0136] Preferably, the aptamer or antibody is labeled using a “cold” labeling method. In the context of the present invention, a cold labeling method is a labeling method that does not involve radioactivity. Thus, the material according to the invention is simpler and safer to produce and use. The presence of a label makes it possible in particular to verify that the grafting of the aptamers has taken place correctly during the production of the material according to the invention.

[0137] The aptamer or antibody may be labeled with one or more fluorophore(s) or with a marker producing a coloration such as the biotin / streptavidin system, or their combination. The term "fluorophore" means a chemical compound capable of emitting light after excitation at a given wavelength. Each fluorophore is excitable at a specific wavelength and emits light at a specific wavelength. A person skilled in the art knows how to choose the fluorophore(s) suitable for implementing the invention. The fluorophores suitable for implementing the present invention may be chosen from the molecules cited in Table 1 below:

[0138] [Tables 1] Fluorophore Name X Excitation (nm) X Emission (nm) Hydroxycoumarin 325 386 Aminocoumarin 350 445 Methoxycoumarin 360 410 Cascade® Blue (375); 401 423 Pacific® Blue 403 455 Pacific Orange™ 403 551 Lucifer Yellow 425 528 Nitrobenzoxadiazole 466 539 R-Phycoerythrin (PE) 480; 565 578 PE-Cy5 Conjugate 480; 565; 650 670 PE-Cy7 Conjugate 480; 565; 743 767 Red 613 480; 565 613 PerCP (Peridinin-Chlorophyll-Protein Complex) 490 675 True Red 490, 675 695 FluorX™ 494 520 Fluorescein 495 519 BODIPY™ FL 503 512 Tetra methyl Rhodamine Iso Thio Cyanate (TRITC) 547 572 X-Rhodamine 570 576 Lissamine Rhodamine B 570 590 Texas Red 589 615 Allophycocyanin (APC) 650 660 APC-Cy7 Conjugate 650; 755 767 Cy2 489 506 Cy3 (512); 550 570; (615) Cy3B 558 572; (620) Cy3.5 581 594; (640) Cy5 (625); 650 670 Cy5.5 675 694 Cy7 743 767 FITC 495 521

[0139] Preferably, the fluorophore is chosen from phycoerythrin (PE), fluorescein isothiocyanate (FITC), the Alexa Fluor™ range, green fluorescent protein (or GFP for "green fluorescent protein" in English). More preferably, the fluorochrome is fluorescein isothiocyanate (FITC for "fluorescein isothiocyanate" in English).

[0140] Labeling the aptamer or antibody can make it possible to verify the good quality of the grafting of the aptamer to the surface of the material. Labeling the aptamer or antibody can also make it possible to signal the binding of the aptamer or antibody to the cell marker of the target cell. For example, when the material comprises a combination of antibodies and / or aptamers, the antibodies and / or aptamers can be labeled with different colors or fluorophores. The labeling can then be removed according to any method well known to those skilled in the art in order to release the aptamer.

[0141] Use

[0142] Another object of the invention is the use of the material grafted with at least one aptamer and / or at least one antibody as described above for the capture of foreign cells circulating in the blood of a patient, and preferably CTCs. The CTCs are preferably derived from the blood of a patient.

[0143] According to this aspect of the invention, the CTCs are derived from breast cancer, lung cancer, prostate cancer, colorectal cancer, bladder cancer, stomach cancer or melanoma.

[0144] The material according to the invention can also be used to improve the effectiveness of chemotherapy and / or to reduce the risk of metastasis formation.

[0145] Indeed, capturing CTCs from the patient's blood makes it possible to reduce, or even eliminate, the quantity of circulating tumor cells from the patient's blood, and therefore to reduce the risks of metastasis formation. Furthermore, the number of CTCs in a blood sample is a prognostic indicator for the patient: reducing this number of cells per volume of blood sample therefore makes it possible to improve the patient's prognosis. Furthermore, reducing the quantity of CTCs in the blood allows chemotherapeutic substances to be more effective, without increasing the dose of substance to be injected into the patient.

[0146] Use

[0147] Another object of the invention is the use of the material grafted by at least one aptamer and / or at least one antibody as described above for the capture of foreign cells circulating in a patient's blood, and preferably CTCs. CTCs are preferably derived from a patient's blood.

[0148] According to this aspect of the invention, the CTCs are derived from breast cancer, lung cancer, prostate cancer, colorectal cancer, bladder cancer, stomach cancer or melanoma.

[0149] The material according to the invention can also be used to improve the effectiveness of chemotherapy and / or to reduce the risk of metastasis formation.

[0150] Indeed, capturing CTCs from the patient's blood makes it possible to reduce, or even eliminate, the quantity of circulating tumor cells from the patient's blood, and therefore to reduce the risks of metastasis formation. Furthermore, the number of CTCs in a blood sample is a prognostic indicator for the patient: reducing this number of cells per volume of blood sample therefore makes it possible to improve the patient's prognosis. Furthermore, reducing the quantity of CTCs in the blood allows chemotherapeutic substances to be more effective, without increasing the dose of substance to be injected into the patient.

[0151] Process for preparing a material according to the invention

[0152] The present invention also relates to a process for preparing the alumina ceramic material according to the invention by grafting at least one aptamer, at least one antibody or their combination onto the alumina ceramic material.

[0153] According to one embodiment, the method comprises at least the following steps: - binding of the binding molecule to the alumina ceramic material by reaction of one or more alkoxy functions of the binding molecule with one or more hydroxyl groups of the alumina ceramic material; and - binding of substituted Taptamer or substituted antibody to the binding molecule by click chemistry reaction.

[0154] Thus, the material according to the invention is first grafted by the binding molecule, then at least one substituted aptamer or at least one substituted antibody is bound to the binding molecule. The step of binding the binding molecule to the alumina ceramic material is therefore carried out before the step of binding the substituted aptamer or the substituted antibody with the binding molecule.

[0155] This makes it possible in particular to produce the material under mild conditions and to obtain good grafting yields of the at least one aptamer and / or antibody onto the material. Furthermore, this variant avoids any risk of direct and undesirable binding of the aptamer or antibody to the ceramic material. As explained above, it is desirable for the aptamer or antibody to be bound to the ceramic material via the binding molecule to avoid too rapid saturation of the material by the steric hindrance linked to foreign cells, preferably circulating tumor cells, attached to the aptamers.

[0156] In the context of the present invention, the mild condition corresponds to synthesis conditions compatible with the use of a biomolecule, for example using a suitable solvent such as acetonitrile to keep it intact with a reaction time of between 4h and 8h, preferably 6h and at a low temperature of between 30°C-120°C, preferably approximately 90°C.

[0157] In the context of the present invention, the expression "click chemistry" designates a class of "biocompatible" chemical reactions used to join a specific biomolecule to a chosen substrate (see https: / / fr.wikipedia.org / wiki / Chimie_click). Typically, click reactions occur in one-pot synthesis, that is, a chemical synthesis in which a reactant undergoes several successive and / or simultaneous reactions in a single reaction mixture.

[0158] According to one embodiment, the at least one aptamer and / or the at least one antibody is substituted and the grafting of the at least one aptamer and / or the at least one antibody onto the alumina ceramic material is carried out via a linker molecule.

[0159] In one embodiment of the invention, the binding of the at least one substituted aptamer or the at least one substituted antibody to the binding molecule by reaction of the terminal alkyne function of the substituted aptamer with the terminal azide function of formula -N=N+=N of the binding molecule. This binding can be done by an alkyne-azide cycloaddition also called a 1,3 dipolar Huisgen cycloaddition. Typically, the reaction of the terminal alkyne function of the substituted aptamer or the substituted antibody with the terminal azide function of formula -N=N+=N of the binding molecule makes it possible to form a 1,2,3-triazole type ring.

[0160] According to one embodiment, the step of binding the binding molecule to the alumina ceramic material is carried out in the presence of an organic solvent, such as toluene, preferably under anhydrous conditions, and advantageously under an inert atmosphere, typically under argon. Before this binding step, the alumina material may be preheated, for example to a temperature above 100°C, in order to dry it and remove moisture.

[0161] According to one embodiment, the step of binding the binding molecule to the alumina ceramic material is carried out at a temperature ranging from 30 to 120°C, typically from 50 to 100°C.

[0162] According to one embodiment, the step of binding the substituted Taptamer or the substituted antibody to the binding molecule is carried out in the presence of one or more organic solvents, such as acetonitrile or an amine, for example of the trimethylamine or triethylamine type.

[0163] According to one embodiment, the step of binding the substituted Taptamer or the substituted antibody to the binding molecule is carried out in the presence of a supported or unsupported catalyst, for example a metal catalyst, for example copper, having triphenylphosphine ligands. Among the catalysts that can be used, copper bromotris(triphenylphosphine) can be mentioned.

[0164] According to one embodiment, the step of binding the substituted aptamer or the substituted antibody to the binding molecule is carried out at a temperature ranging from 30 to 120°C, typically from 50 to 100°C, preferably about 90°C.

[0165] The present invention also relates to an aptamer, an antibody or their combination grafted onto an alumina ceramic material according to the invention for the capture of circulating foreign cells, preferably circulating tumor cells.

[0166] The present invention also relates to a method for capturing circulating foreign cells, preferably circulating tumor cells, using the material according to the invention.

[0167] Device

[0168] The present invention also relates to a device for capturing circulating foreign cells, preferably circulating tumor cells, using the material according to the invention as described above.

[0169] According to one embodiment, the device according to the invention comprises the material according to the invention as described above as a material for capturing circulating tumor cells. The device may in particular be similar in its operation to that described in international application WO 2017 / 186626 AL

[0170] Preferably, the device according to the invention is an extracorporeal device, making it possible to bring the patient's peripheral blood into contact with the material grafted by at least one aptamer according to the invention.

[0171] The device according to the invention may comprise a housing for putting the extracorporeal blood circulation of the patient with the material according to the invention, comprising at least one inlet for the entry of blood into the housing and an outlet for the exit of blood from the housing. The housing may house a capture tool.

[0172] In one embodiment of the invention, the housing may have a tubular shape.

[0173] The capture tool may have a helical shape. In particular, the helical or screw or Archimedean screw structure extends longitudinally around an axis of rotation and is fixed to the capture chamber by means of a fixing system. Preferably, each end of the axis of rotation is provided with a magnet. In this variant, the housing further comprises a magnet, and in particular with a pole opposite to the magnet present on the end of the axis of rotation. Thus, the presence of the magnets on the one hand on the housing and on the other hand on the ends of the axis of rotation of the capture tool makes it possible to create a magnetic field which keeps the capture tool suspended in its housing. Thus kept levitating in the housing of the device, the capture tool does not become blocked by blood pressure and continues to treat the patient's blood.

[0174] More specifically, the movable capture element has the shape of a helix or a spiral. This particular shape is used to ensure a smooth circulation of the blood fluid and at the same time a larger surface area in contact with the circulating blood in order to increase the probability of binding between the entity to be removed, for example the tumor cell, and the binding agents, for example the antibody or the aptamer. Preferably, the helical surface may extend over the entire length of the capture chamber. However, a configuration in which the length of the helix is ​​less than the length of the capture chamber and within which there are a plurality of helical structures placed in series may also be used. Of course, thanks to such a configuration, the length of the entire apparatus must necessarily be increased.

[0175] According to embodiments of the present inventions, the movable capture element is configured to facilitate contact between the reagent surface of the apparatus and the target cells. Thus, any type of movable helix, double helix, or other movable 3D structure designed to facilitate this contact is included in this invention.

[0176] In one embodiment, the capture tool may be manufactured or covered in whole or in part by the material according to the invention. The internal walls of the housing may also be covered in whole or in part by the material according to the invention.

[0177] The device according to the invention makes it possible in particular to bring the total volume of blood of a patient into contact with the material according to the invention. Depending on the size and weight of the patient, it is estimated that the total volume of blood of a patient is between 3L and 5L. Preferably, the device according to the invention makes it possible to bring the total volume of blood of a patient into contact several times, so as to maximize the capture of the patient's circulating tumor cells.

[0178] The device according to the invention may also comprise a pump in order to pump the patient's blood. The device according to the invention may also comprise filters. FIGURES

[0179] Figure 1 shows a schematic of the formula of the anti-MUC-1 aptamer substituted with a hydrocarbon group comprising a terminal alkyne.

[0180] Figure 2 is an infrared spectrum of AzPTES as produced before its binding to the aptamer and ceramic.

[0181] Figure 3 is a diagram summarizing the reaction on dense alumina according to Example 1.

[0182] EXAMPLES

[0183] The following examples are given as illustrations of the present invention, and are not intended in any way to limit its scope.

[0184] Examples of preparation by grafting an aptamer onto an alumina ceramic are described below in order to prepare an alumina ceramic grafted with at least one aptamer in accordance with the invention.

[0185] The ceramic used is a dense A12O3 alumina ceramic of DIN C799 type, produced by the company SCERAM. According to the supplier's specifications, the C799 alumina comprises 99.7% Al2O3 alumina and has a density of 3.8 and an absolute density of 3.9 g / cm3. The open porosity of this ceramic is 0%.

[0186] The aptamer used is a 72-base single-stranded DNA oligonucleotide designed by the SELEX method to bind to the MUC-1 protein and has the sequence: 5' GGGAGACAAGAAT AAACGCTCAAGC AGTTGATCCTTTGGATACCCTGG TTCGACAGGAGGCTC ACAACAGGC3'

[0187] In order to be able to react with other molecules, the aptamer was modified at its 5' end by the addition of a hydrocarbon group comprising a terminal alkyne group. The reaction of the azide of the linker molecule with the terminal alkyne group of the substituted aptamer forms a triazole ring. The formula scheme of the substituted aptamer is shown in Figure 1. The aptamer thus substituted is used for the implementation of Examples 1 and 2. The substituted anti-MUC-1 aptamer is custom-produced and obtained commercially.

[0188] Example 1 Method for grafting an anti-MUC-1 aptamer onto a dense alumina ceramic

[0189] Example 1 illustrates the preparation method according to the invention in which the linker molecule is first bound to the alumina ceramic before a substituted anti-MUC-1 aptamer is bound to the linker molecule. The entire synthesis reactions are summarized in Figure 3.

[0190] Step 1 - Synthesis of the linker molecule 3-azidopropvl)triethoxvsilane (AzPTES U

[0191] 1.93 g of chlorosilane (8 mmol), 0.2 g of Kl (1.2 mmol) and 1.56 g of NaN3 (24 mmol) are mixed in a 50 ml Schlenk tube. The system is placed under vacuum and then under an argon atmosphere and 10 ml of DMF (N,N-dimethylformamide) are introduced under argon. The reaction is started for 24 h at 80 °C and 330 rpm. The solution is then yellow. After 24 h, the solution has become white and has two phases. Once the medium has returned to room temperature, the solution is filtered through a Celite® 545 filter (approximately 1 cm) soaked in 15 ml of DMF on a No. 3 frit, then rinsed with 5 ml of DMF. DMF is evaporated using a rotary evaporator (70°C, 90 rpm).

[0192] Dichloromethane (30 ml) is added to the solution. This is washed twice with 30 ml of water, then the organic phase is dried over MgSO4, then filtered and placed in a rotary evaporator (40°C, 90 rpm) to remove the dichloromethane and any traces of DMF. White residues are observed. The solution is cent- trifugee for 5 min at 1500 rpm. The yellow, oily supernatant containing AzPTES is collected and weighed: 1.1 g (4 mmol) of product is recovered. The molar yield of this step is approximately 56%. AzPTES has the formula:

[0193] [Chem.l]

[0194] The results of characterization of AzPTES by infrared and NMR are as follows: - FR-IR (ATR, 4 cm resolution 8 analyses / sample): Band observed at 2100 cm 1 characteristic of the N3 group. Other bands observed: 1075 cm-1 characteristic of the Si-OC group, 775 cm 1 characteristic of the Si-C group. The infrared spectrum of AzPTES is shown in Figure 3. 1H NMR (500 MHz. CDC13. 25°C. ô, ppm): 0.69 (m, 2H, CH2-Si), 1.23 (t, 9H, CH3, J = 7.0 Hz), 1.71 (m, 2H, CH2), 3.26 (t, 2H, CH2-N3, J = 6.9 Hz), 3.83 (q, 6H, CH2-O, J = 7.0 Hz) 13C NMR (500 MHz. CDC13. 25°C. ô, ppm): 7.7 (CH2-Si), 18.3 (CH3), 22.7 (CH2), 53.9 (CH2-N3), 58.5 (CH2-O)

[0195] Step 2 - Bonding of AzPTES to alumina ceramic.

[0196] A 14 mm diameter, 4 mm thick alumina ceramic pellet is used.

[0197] The alumina ceramic pellet A12O3 is placed in an oven at 120°C overnight. A 50 mL two-necked flask is placed in an oven at 120°C for 5 minutes to remove any trace of moisture from the flask. The ceramic is then introduced into the two-necked flask. The latter is placed under vacuum and then under argon. 7 ml of anhydrous toluene is introduced under argon. The mixture is brought to 60°C, 330 rpm. Once the temperature of 60°C is reached, 2 nmol of AzPTES is introduced under argon, drop by drop, then a condenser is installed on the two-necked flask and placed under argon. The reaction is carried out for 3 h at 90°C, 330 rpm.

[0198] After 3 h, the ceramic is washed with 10 ml of toluene for 2 min in an ultrasonic bath (water, power: 100%, 80 Hz) three times, then once with 10 ml of 95% ethanol.

[0199] X-ray photoelectronic spectrometry (XPS) analysis detects the presence of silicon and nitrogen, evidence that binding of DNA-bound AzPTES to ceramic alumina worked. This is because silicon and nitrogen are not among the chemical elements present in ceramics. The presence of silicon on the surface of the material indicates that the AzPTES bond to the material worked, and the presence of nitrogen indicates the presence of single-stranded DNA forming the aptamer.

[0200] Step 3 - Binding of the anti-MUC-1 aptamer to the AzPTES bound to the alumina ceramic.

[0201] 4.8 mg of CuBr(PPh3)3 catalyst, 1.5 μl of trimethylamine and 7 ml of acetonitrile are mixed with the ceramic bound to AzPTES. The mixture is brought to 60°C, 330 rpm. Once the temperature of 60°C is reached, the DNA is introduced dropwise. A condenser is placed on the flask and the reaction is carried out for 6 hours at 90°C, 330 rpm for binding of the aptamer to AzPTES. The reaction medium is then transparent.

[0202] At the end of the reaction, the catalyst (CuBr(PPh3)3) is removed by filtration of the solution using a filter (porosity 0.45 pm) on a syringe. The ceramic is washed three times with acetonitrile and then once with ethanol in an ultrasonic bath as described in step 1.

[0203] The alumina ceramic is then cleaned with 3 mL of sterile 95% ethanol. The pellet is then stored at 4°C to avoid or reduce degradation of the aptamer grafted onto the ceramic. The material thus grafted can be stored for 1 month at 4°C.

[0204] The reaction medium and the washing media (acetonitrile and ethanol) are added and then placed in the rotary evaporator at 40°C, 90 rpm. Once the solvents have evaporated, 200 μL of ultrapure water are added to the DNA desorbed by the washes. The ungrafted DNA is then quantified in visible UV at 260 nm and 280 nm according to any method well known to those skilled in the art.

[0205] An infrared analysis (ATR, resolution 4 cm ', 8 analyses / sample) makes it possible to observe a band at 3325.35 cm1, characteristic of the -NH functions of DNA, as well as a broad band at 2114.90 cm 1 characteristic of the alkyne group, and a band at 1639.12 cm 1 characteristic of the ketones of DNA.

[0206] The binding efficiency of the aptamer on the ceramic material according to the method of Example 2 is approximately 44%.

[0207] Example 2

[0208] Example 1 was repeated using an aptamer labeled at its 3' end with FITC. The material thus prepared was observed under a confocal microscope. It was observed that the material prepared in accordance with the method according to the invention was homogeneously grafted by the aptamer.

[0209] Conclusion

[0210] The present invention therefore provides an alumina ceramic material grafted with an aptamer, an antibody or their combination, the grafting preferably being carried out via a linker molecule, as well as a method for preparing such a material. The material according to the invention therefore makes it possible to provide a biocompatible and hemocompatible material for capturing foreign cells, preferably circulating tumor cells present in a patient's blood. The material according to the invention is inert with respect to the patient's blood so that it does not capture any element circulating in the patient's blood other than the targeted foreign cells and does not cause any depletion, denaturation, coagulation or reaction likely to harm the patient. The material according to the invention also makes it possible to treat the total blood volume of a patient, or even to allow several passages of the total blood volume in contact with the material to capture and remove the maximum possible number of circulating cells from the patient's blood. The material according to the invention can therefore be used for therapeutic purposes to reduce the risk of metastasis formation or the risk of cancer recurrence.The material according to the invention can also be used to improve the effectiveness of a chemotherapy treatment.

[0211] The material according to the invention can also be used in the context of a device for capturing circulating foreign cells, preferably an extracorporeal device for capturing circulating tumor cells.

Claims

Claims

1. Alumina ceramic material grafted with at least one aptamer, at least one antibody or their combinations.

2. Material according to claim 1 wherein the at least one aptamer, the at least one antibody or their combination is grafted to said alumina ceramic material by a linker molecule.

3. Material according to claim 2 wherein the linking molecule is a trialkoxysilane of formula N=N+=NL-Si(ORl)(OR2)(OR3) in which L denotes a linear, branched or cyclic divalent hydrocarbon radical comprising 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, and RI, R2, R3 are identical or different and represent a linear or branched alkyl group comprising 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms.

4. Material according to one of the preceding claims in which the at least one aptamer is single-stranded DNA.

5. Material according to one of the preceding claims in which the at least one aptamer or the at least one antibody is a substituted aptamer or an antibody substituted by at least one linear, branched or cyclic hydrocarbon group comprising a terminal alkyne function having the formula C=CH and from 3 to 20 carbon atoms, preferably from 10 to 15 carbon atoms, said hydrocarbon group being optionally substituted by one or more heteroatoms.

6. Material according to one of the preceding claims wherein the at least one aptamer or the at least one antibody is capable of binding to at least one of the proteins chosen from mucin 1 (MUC-1), EpCam, HER-2, EGFR, vimentin, E-cadherin, N-cadherin, OB-cadherin, CD44v6, CD44v8, PSA, cytokeratin 8, cytokeratin 19, ABC-G2 and combinations thereof, preferably mucin protein 1 (MUC-1).

7. Material according to one of the preceding claims in which the at least one aptamer, the at least one antibody or their combination is linked to at least one labeling molecule.

8. Process for preparing the material according to one of claims 1 to 7, comprising the grafting of the alumina ceramic with at least one aptamer, at least one antibody or their combination.

9. The method of claim 8, wherein the at least one aptamer, at least one antibody or their combination is grafted to said alumina ceramic material by a linker molecule, said method comprising at least the following steps: - binding of the binding molecule to the alumina ceramic material by reaction of one or more alkoxy functions of the binding molecule with one or more hydroxyl groups of the alumina ceramic material; and - binding of the aptamer or antibody to the binding molecule by click chemistry reaction.

10. Method according to claim 8 or 9 in which the at least one aptamer or the at least one antibody is a substituted aptamer or an antibody substituted by at least one linear, branched or cyclic hydrocarbon group comprising a terminal alkyne function having the formula C=CH and from 3 to 20 carbon atoms, preferably from 10 to 15 carbon atoms, said hydrocarbon group being optionally substituted by one or more heteroatoms.

11. A method according to one of claims 8 to 10 wherein the aptamer or antibody is substituted and the binding of the substituted aptamer or substituted antibody to the binding molecule is carried out by reaction of the terminal alkyne function of the substituted aptamer with the terminal azide function of formula -N=N+=N of the binding molecule.

12. Device for capturing circulating foreign cells, preferably circulating tumor cells, comprising the material according to one of claims 1 to 7 and at least one housing.